Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell ...

    Research Article last updated 11/05/2012 - 8:57am.

  2. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

    ... This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Adverse effects of azacitidine: onset, duration, and treatment

    ... with survivals of close to only 1 year. The use of azacitidine , a DNA methyltransferase inhibitor, in this group of patients ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Azacitidine adverse effects in patients with myelodysplastic syndromes

    ... May 12, 2011 Azacitidine is now considered one of the standard-of-care agents for ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

    ... retrospective cohort of 282 higher-risk MDS treated with azacitidine , including 32 patients who concomitantly received an ESA for a median of 5.8months after azacitidine onset. Forty-four percent of ESA and 29% of no-ESA patients reached ...

    Research Article last updated 07/28/2014 - 9:30am.

  6. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry

    ...

    Research Article last updated 10/12/2015 - 10:22am.

  7. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... CC-486 is an oral formulation of the epigenetic modifier azacitidine . In an expanded phase 1 trial, CC-486 demonstrated clinical and ...

    Research Article last updated 06/23/2016 - 10:17am.

  8. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... syndromes with excess blasts after failure of azacitidine or decitabine treatment. METHODS: We did this ...

    Research Article last updated 06/07/2016 - 11:10am.

  9. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

    ... Abstract The hypomethylating agents azacitidine and decitabine are standard therapy for ... who were treated with decitabine after primary or secondary azacitidine failure at the University of Maryland Greenebaum Cancer Center. ...

    Research Article last updated 10/02/2014 - 10:13am.

  10. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

    ... Survival after azacitidine (AZA) failure in higher-risk myelodysplastic syndromes (MDS) ...

    Research Article last updated 01/20/2015 - 1:14pm.